Innocan Pharma's Public Offering Registration Filing
Innocan Pharma Corporation (CSE: INNO, OTCQB: INNPF) has recently made significant strides by submitting a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed public offering of Units. This initiative marks an exciting chapter for the company as it aims to expand its reach in the pharmaceutical market.
Details of the Proposed Offering
The proposed offering includes Units, each composed of one Common Share and one purchase warrant from Innocan. The exercise price and terms of the Warrants will be based on market conditions, enhancing the attractiveness of the offering to potential investors.
Potential Nasdaq Listing
Innocan Pharma is on a path to list its Common Shares and Warrants on the Nasdaq Capital Market under symbols INNP and INNPW. This step will further solidify its presence in the U.S. market and is expected to attract more investors, giving the company the necessary capital for its growth initiatives.
Management and Underwriting Details
Managing the offering is ThinkEquity, serving as the sole book-running manager. Their expertise in the securities market is anticipated to facilitate a successful offering process, providing both guidance and support for Innocan.
Prospectus Availability and SEC Regulations
Investors should be aware that the offerings will be conducted solely through a prospectus. Preliminary copies of this prospectus will be available upon request. It is essential for interested parties to note that the registration statement must become effective before any sales can take place, adhering strictly to SEC regulations.
CEO's Vision for Innocan
Iris Bincovich, the CEO of Innocan Pharma, expressed excitement about this strategic move. She stated, "The entire Innocan Pharma team and I are thrilled with having taken this significant step in the process of our listing on the Nasdaq, which opens up exciting new opportunities for us on multiple levels." This sentiment emphasizes the company's optimism as it charts a new course in the pharmaceutical landscape.
Innocan's Innovative Offerings
Innocan Pharma is making waves in both the pharmaceutical and wellness sectors. It has developed a cutting-edge CBD-loaded liposome drug delivery system that ensures precise dosing and prolonged release of synthetic CBD, serving as an effective alternative for pain management without opioids. In addition, Innocan is expanding into the wellness arena with a wide range of self-care and beauty products, promoting healthier lifestyles through innovative online sales strategies via its subsidiary, BI Sky Global Ltd.
Contact Information for Further Inquiries
For additional queries about the offering or the company’s products, contact:
Iris Bincovich, CEO
Phone: +1-516-210-4025
International: +972-54-3012842
UK: +44-2037699377
Email: info@innocanpharma.com
Frequently Asked Questions
What is Innocan Pharma's recent announcement?
Innocan Pharma announced the public filing of a registration statement with the SEC for a proposed public offering of Units.
What does each Unit in the offering include?
Each Unit consists of one Common Share and one purchase warrant.
Who is managing the public offering?
The offering is being managed by ThinkEquity as the sole book-running manager.
Where can investors obtain the prospectus for the offering?
Investors can request the preliminary prospectus, which will be made available once the registration statement is effective.
What is Innocan Pharma's main focus in its product development?
Innocan focuses on developing CBD-based pharmaceuticals and high-performance wellness products to improve health and quality of life.
